Viewing Study NCT06063018


Ignite Creation Date: 2025-12-25 @ 4:32 AM
Ignite Modification Date: 2025-12-26 @ 3:34 AM
Study NCT ID: NCT06063018
Status: RECRUITING
Last Update Posted: 2023-10-02
First Post: 2023-09-11
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer
Sponsor: Peking Union Medical College Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module